BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37431107)

  • 1. Impact of race/ethnicity and socioeconomic status on incident and prevalent esophageal cancer in patients with Barrett's esophagus.
    Zhou MJ; Ladabaum U; Triadafilopoulos G; Clarke JO
    Dis Esophagus; 2023 Nov; 36(12):. PubMed ID: 37431107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
    Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
    Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.
    Bhat S; Coleman HG; Yousef F; Johnston BT; McManus DT; Gavin AT; Murray LJ
    J Natl Cancer Inst; 2011 Jul; 103(13):1049-57. PubMed ID: 21680910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review with meta-analysis: prevalent vs. incident oesophageal adenocarcinoma and high-grade dysplasia in Barrett's oesophagus.
    Visrodia K; Singh S; Krishnamoorthi R; Ahlquist DA; Wang KK; Iyer PG; Katzka DA
    Aliment Pharmacol Ther; 2016 Oct; 44(8):775-84. PubMed ID: 27562355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study.
    Wani S; Holmberg D; Santoni G; Kauppila JH; Farkkila M; von Euler-Chelpin M; Shaheen NJ; Lagergren J
    Gastroenterology; 2023 Oct; 165(4):909-919.e13. PubMed ID: 37279832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
    Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
    Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.
    Thota PN; Vennalaganti P; Vennelaganti S; Young P; Gaddam S; Gupta N; Lieberman D; Sampliner R; Falk GW; Mathur S; Kennedy K; Cash BD; Moawad F; Bansal A; Spaander MC; Bruno MJ; Vargo J; Sharma P
    Gastroenterology; 2017 Apr; 152(5):987-992. PubMed ID: 27988383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
    Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
    Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
    United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
    Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
    Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis.
    Yousef F; Cardwell C; Cantwell MM; Galway K; Johnston BT; Murray L
    Am J Epidemiol; 2008 Aug; 168(3):237-49. PubMed ID: 18550563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.
    Sharma P; Falk GW; Weston AP; Reker D; Johnston M; Sampliner RE
    Clin Gastroenterol Hepatol; 2006 May; 4(5):566-72. PubMed ID: 16630761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
    Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
    Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal Adenocarcinoma.
    Hamade N; Vennelaganti S; Parasa S; Vennalaganti P; Gaddam S; Spaander MCW; van Olphen SH; Thota PN; Kennedy KF; Bruno MJ; Vargo JJ; Mathur S; Cash BD; Sampliner R; Gupta N; Falk GW; Bansal A; Young PE; Lieberman DA; Sharma P
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):864-868. PubMed ID: 30012433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer.
    Falk GW; Thota PN; Richter JE; Connor JT; Wachsberger DM
    Clin Gastroenterol Hepatol; 2005 Nov; 3(11):1089-94. PubMed ID: 16271339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.